According to the Food and Drug Administration of the United States, Bayer AG is guilty of misleading the public through two advertisements for their birth control pill, Yaz. Health regulators have issued a warning to the company about this in a letter that was released on October 7, 2008.

Highlights of the FDA charges
a. According to the FDA, Bayer has wrongly portrayed the benefits of the Yaz drug.
b. Bayer had run two advertisements on the drug.
c. Bayer has said it will stop running the only one of the two ads currently in use.
d. Though one campaign ended in 2007, the other is still running.
e. The former ad seem to suggest that it is approved for any severity of the symptoms presented, regardless of whether their symptoms are actually severe enough to constitute PMDD.
f. The current ad suggests that women are symptom-free after using the pill.
g. However, according to the FDA, elimination of symptoms has not been demonstrated by substantial evidence or substantial clinical experience.
h. The public has been mislead into believing that the pills are approved for relieving premenstrual syndrome.
i. The advertisements minimize the drug's risks.
j. The drug is cleared for a serious condition called premenstrual dysphoric disorder (PMDD), which causes anxiety, tension, persistent anger and other symptoms.
k. Blood clots are among the potential side effects of these pills.